Yes cash runway is very tight indeed! Mesoblast does have access...

Yes cash runway is very tight indeed!
Mesoblast does have access to an additional US$30 million from Oaktree if it can meet certain milestones (undisclosed) by 30 September 2023 and the unusable US$35 million reduces to US$25 million if the BLA is approved by the FDA.

"

The New Debt Facility is secured by substantially all our assets and contains covenants that impose certain restrictions, including a limitation on incurring additional debt and maintaining a minimum cash reserve. Mesoblast is required to maintain a minimum unrestricted cash balance of US$35 million, which would reduce to US$25 million upon FDA approval of Remestemcel-L for SR-aGVHD.

On December 20, 2021, the Initial Lender assigned the initial loan and all its interests in the New Debt Facility to the Oaktree Shareholders.

On December 22, 2022, we entered into the First Amendment to the New Debt Facility. Under the terms of the First Amendment, the availability of up to an additional US$30.0 million under the New Debt Facility was extended, subject to the achieving of certain milestones on or before September 30, 2023. As consideration, we issued warrants to purchase 455,000 ADSs to affiliated funds of Oaktree Capital in the Private Placement at an exercise price of US$3.70 per ADS. The Warrants have an expiry date of seven years from the date of issuance.

"
From the Form F3 lodged withe SEC recently --https://www.benzinga.com/secfilings/23/03/31488387/mesoblast-ltd-formf-3
Otherwise its a CR, whatever form that may take. So the shorters a betting we cannot make the tight timelines.